Fox Chase Cancer Center News

PHILADELPHIA, PA (March 1, 2016) — Fox Chase Cancer Center, in partnership with its Board of Associates, will present its signature fundraising event In Vino Vita Benefit and Wine Auction on Saturday, April 9, 2016 at Vie.

PHILADELPHIA (February 22, 2016) — Eric M. Horwitz, MD, chair of radiation oncology at Fox Chase Cancer Center, has been appointed to the Pennsylvania Task Force on Prostate Cancer and Related Chronic Prostate Conditions (PCTF) by Pennsylvania Secretary of Health Dr. Karen Murphy.

PHILADELPHIA (February 22, 2016) –  Fox Chase Cancer Center – Temple Health researchers provide conclusive evidence that Bap1 is a bona fide tumor suppressor gene that strongly interacts with environmental factors to control the risk of developing malignant mesothelioma and other cancers. The findings, reported February 22^nd in Cancer Research, shed light on the recently recognized BAP1 cancer syndrome, paving the way for new early detection and therapeutic strategies for a range of highly aggressive, hard-to-treat cancers.

PHILADELPHIA (February 19, 2016) – Bone marrow transplantation has boosted survival rates from nearly zero to more than 85 percent for some blood cancers. In spite of this progress, it can produce serious side effects such as graft-versus-host disease. The clinical prognosis varies widely across individuals.

ABU DHABI (Feb. 18, 2016) —Fox Chase Cancer Center, Philadelphia, has signed an agreement  with Universal Hospital, Abu Dhabi, to design program services as Universal Hospital looks to establish a Bone Marrow Transplant (BMT) program within the United Arab Emirates (UAE).

PHILADELPHIA (February 18, 2016) — Robert G. Uzzo, MD, FACS, a nationally recognized leader in urologic oncology from Fox Chase Cancer Center–Temple Health, is the recent recipient of the 36th Annual Ralph E. Hopkins Jackson Hole Seminar Series in Urology Award.

PHILADELPHIA (February 16, 2016) – Phenylketonuria, also known as PKU, is the most common inherited disease affecting amino acid metabolism. In a study published February 15^th in Proceedings of the National Academy of Sciences, Fox Chase Cancer Center – Temple Health researchers made tremendous strides toward that goal by shedding new light on the structure of phenylalanine hydroxylase (PAH)—the enzyme that is defective in PKU patients.

PHILADELPHIA (February 16, 2016) – Fox Chase Cancer Center – Temple Health researchers have identified a way forward for personalized cancer treatments for a wide range of cancers by understanding how to stimulate the activity of a potent anticancer protein called TRAIL. ONC201 not only stimulates TRAIL, but also the death receptor for TRAIL on tumor cells.